| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/24/2003 | US20030139452 Pyrazole-derived kinase inhibitors and uses thereof |
| 07/24/2003 | US20030139447 Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof |
| 07/24/2003 | US20030139443 Anxiolytic agents; veterinary medicine |
| 07/24/2003 | US20030139435 N-heterocyclic inhibitors of TNF-alpha expression |
| 07/24/2003 | US20030139428 Purine derivatives for treatment of gastrointestinal disorders, immunological disorders, neurological disorders |
| 07/24/2003 | US20030139426 Pyrazolopyrimidines as CRF antagonists |
| 07/24/2003 | US20030139423 Central nervous system disorders; psychological disorders |
| 07/24/2003 | US20030139421 Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain |
| 07/24/2003 | US20030139418 Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists |
| 07/24/2003 | US20030139413 Novel 1,3-dihydro-2h-indol-2-one derivatives, preparation method and pharmaceutical composition containing them |
| 07/24/2003 | US20030139410 Use of modified pyrimidine compounds to promote stem cell migration and proliferation |
| 07/24/2003 | US20030139408 Analgesics; cognition activators |
| 07/24/2003 | US20030139407 Efficient synthesis of 5-heteroatom-containing -pyrazoles |
| 07/24/2003 | US20030139406 Antiinflammatory agents; antidepressants; respiratory system disorders; cognition activators |
| 07/24/2003 | US20030139402 Antiinflammatory agents; Alzheimer's disease; cardiovascular disorders |
| 07/24/2003 | US20030139395 Synergistic mixture; psychological disorders, central nervous system disorders, cardiovascular disorders |
| 07/24/2003 | US20030139394 Dibenzodiazepine derivatives, their preparation and use |
| 07/24/2003 | US20030139391 Efficacious dosage regimen of galantamine that reduces side effects |
| 07/24/2003 | US20030139384 Transdermal supplying testosterone |
| 07/24/2003 | US20030139381 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
| 07/24/2003 | US20030139376 Lipoxin A4 analogs |
| 07/24/2003 | US20030139353 Using topoisomerase inhibitor; antiarthritic agents; respiratory system disorders; skin disorders |
| 07/24/2003 | US20030139350 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents |
| 07/24/2003 | US20030139346 Polymer stabilized neuropeptides |
| 07/24/2003 | US20030138926 Novel polynucleotides and polypeptides encoded thereby |
| 07/24/2003 | US20030138839 Polypeptide comprising ubiquitination regulating domain; antiproliferative agents; neuroprotectants; cancer diagnosis |
| 07/24/2003 | US20030138803 Identification and use of molecules implicated in pain |
| 07/24/2003 | US20030138772 Polymerase chain reactions to screen and isolate parvovirus DNA obtained from tissue and/or cells without coinfection by helper viruses; gene therapy |
| 07/24/2003 | US20030138505 Intradermal-penetration agents for topical local anesthetic administration |
| 07/24/2003 | US20030138503 Topical pharmaceutical formulations and methods of treatment |
| 07/24/2003 | US20030138440 Multimeric proteins and methods of making and using same |
| 07/24/2003 | CA2474239A1 Substituted pyridazinones as inhibitors of p38 |
| 07/24/2003 | CA2474141A1 Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof |
| 07/24/2003 | CA2473893A1 Stable salts of o-acetylsalicylic acid with basic amino acids ii |
| 07/24/2003 | CA2473441A1 Beta-secretase inhibitors |
| 07/24/2003 | CA2473374A1 Phenyl sulfoxides and phenyl sulfones |
| 07/24/2003 | CA2473236A1 Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues |
| 07/24/2003 | CA2473229A1 Selective melanin-concentrating hormone type -1 receptor agonists |
| 07/24/2003 | CA2473115A1 Remedy for dysmnesia |
| 07/24/2003 | CA2472746A1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
| 07/24/2003 | CA2472619A1 Fused pyrimidine derivates as rho-kinase inhibitors |
| 07/24/2003 | CA2472469A1 1,3-disubstituted and 1,3,3,-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| 07/24/2003 | CA2472419A1 Coumarin derivatives, process for their production and use thereof |
| 07/24/2003 | CA2472204A1 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases |
| 07/24/2003 | CA2472203A1 The use of il6r/il6 chimera in nerve cell regeneration |
| 07/24/2003 | CA2472168A1 Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
| 07/24/2003 | CA2471744A1 Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs3 upregulation |
| 07/24/2003 | CA2471480A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 07/24/2003 | CA2471311A1 Aromatic thioether liver x-receptor modulators |
| 07/24/2003 | CA2470649A1 Mmp inhibitors |
| 07/24/2003 | CA2470421A1 Use of a novel cell surface protease from group b streptococcus |
| 07/24/2003 | CA2469800A1 Methods for the induction of professional and cytokine-producing regulatory cells |
| 07/24/2003 | CA2469435A1 Modulators of lxr |
| 07/24/2003 | CA2464131A1 Compositions and methods for controlled release |
| 07/23/2003 | EP1329511A1 Polypeptide having phospholipase a2 actiivty |
| 07/23/2003 | EP1329508A1 Novel g protein-coupled receptor protein and dna thereof |
| 07/23/2003 | EP1329499A2 Growth factor-responsive progenitor cells which can be proliferated in vitro |
| 07/23/2003 | EP1329226A2 Hapten-Carrier Conjugates for use in Drug Abuse Therapy |
| 07/23/2003 | EP1329223A1 Expression potentiator for protein synthesis regulatory gene |
| 07/23/2003 | EP1329222A1 Isoflavone compositions for use in medicine |
| 07/23/2003 | EP1328816A2 Regulation of neutral development by daedalos |
| 07/23/2003 | EP1328653A2 Highly expressible genes |
| 07/23/2003 | EP1328646A2 Regulation of human adenylate cyclase, type iv |
| 07/23/2003 | EP1328641A2 Polynucleotides isolated from e. coli of nature b2/d+ a-, and uses thereof |
| 07/23/2003 | EP1328634A2 Genes expressed in the cell cycle |
| 07/23/2003 | EP1328630A2 Secreted proteins |
| 07/23/2003 | EP1328629A2 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 07/23/2003 | EP1328624A2 B7-like molecules and uses thereof |
| 07/23/2003 | EP1328619A1 Human tuberoinfundibular peptide of 39 residues |
| 07/23/2003 | EP1328548A2 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 07/23/2003 | EP1328525A2 2,3,4,5-tetrahydro-1h-[1,4]diazepino[1,7-a]indole compounds |
| 07/23/2003 | EP1328522A2 Estrogen receptor modulators |
| 07/23/2003 | EP1328521A2 A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| 07/23/2003 | EP1328516A1 Novel neurokinin antagonists, method for the production thereof and pharmaceutical compositions containing said compounds |
| 07/23/2003 | EP1328515A1 Indoline derivatives and their use as 5-ht2 receptor ligands |
| 07/23/2003 | EP1328514A1 Amide derivatives as nmda receptor antagonists |
| 07/23/2003 | EP1328319A1 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases |
| 07/23/2003 | EP1328298A1 Methods and compositions for modulating t cell activation and uses thereof |
| 07/23/2003 | EP1328295A2 New interferon beta-like molecules |
| 07/23/2003 | EP1328294A2 Combination use of acetylcholinesterase inhibitors and gaba-a inverse agonists for the treatment of cognitive disorders |
| 07/23/2003 | EP1328284A1 Novel medicinal herbal composition for treating liver diseases and hiv |
| 07/23/2003 | EP1328272A1 Nf-kappa-b inhibitors |
| 07/23/2003 | EP1328271A2 Method for the treatment of neurological and neuropsychological disorders |
| 07/23/2003 | EP1328270A2 Method for the treatment of neurological and neuropsychological disorders |
| 07/23/2003 | EP1328261A2 Treatment of neurodegenerative disease |
| 07/23/2003 | EP1328236A2 Methods of decreasing or preventing pain using spicamycin derivatives |
| 07/23/2003 | EP1254134B1 1,3-dihydro-2h-indol-2-one derivatives,and their use as ligands for v1b or v1b and v1a arginine-vasopressin-receptors |
| 07/23/2003 | EP1235573B1 Combination of riluzole and gabapentin and use thereof for the treatment of motor neuron disorders |
| 07/23/2003 | EP1228073B1 Imidazole compounds used as phosphodiesterase vii inhibitors |
| 07/23/2003 | EP1204654B1 Benzofurylpiperazines: 5-ht2c serotonin receptor agonists |
| 07/23/2003 | EP1189608B1 Levodopa/carbidopa/entacapone pharmaceutical preparation |
| 07/23/2003 | EP1161252B1 Use of extracts from ginkgo biloba leaves for treating sleep disorders |
| 07/23/2003 | EP1086096B1 Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors |
| 07/23/2003 | EP1032575B1 2,3-diaryl-pyrazolo(1,5-b)pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors |
| 07/23/2003 | EP1017711B1 Monocyclic compounds with four bifunctional residues having nk-2 antagonist action |
| 07/23/2003 | EP1007024B1 Delayed-release dosage forms of sertraline |
| 07/23/2003 | EP0929528B1 Aralkyl and aralkylidene heterocyclic lactams and imides |
| 07/23/2003 | EP0920323B1 Novel use of phospholipids of animal origin in therapy and/or dietetics |
| 07/23/2003 | EP0811011B1 Carbohydrate conjugated bio-active compounds |
| 07/23/2003 | EP0628033B1 Benzodiazepin derivatives useful as cck-receptor antagonists |